MDxHealth
Palmetto Releases Draft LCD for Prostate Cancer Risk Stratification Tests
Under the local coverage determination, tests to help identify patients who may benefit from a prostate biopsy would be covered under certain conditions.
MDxHealth 2020 Revenues Up 57 Percent
Billable test volume for the company's ConfirmMDx and SelectMDx prostate cancer test fell year over year, but rose sequentially from the third quarter.
Oppenheimer Initiates Coverage of MDxHealth at Outperform
The investment bank cited its expectation for a positive coverage decision from Medicare for the company's SelectMDx prostate cancer test, among other reasons.
MDxHealth Q3 2020 Revenues Drop 6 Percent
For the three months ended Sept. 30, the Belgian molecular diagnostic firm's revenues fell to $4.5 million from $4.7 million in Q3 2019.
MDxHealth H1 2020 Revenues Down 9 Percent on Declining Test Volumes
The company said billable volume for its ConfirmMDx prostate cancer test fell 12 percent year over year, and volumes for its SelectMDx test fell 48 percent.